Arovella Therapeutics Limited (ASX:ALA)
Arovella Therapeutics Limited (ASX:ALA), previously SUDA Pharmaceuticals Ltd (ASX:SUD), is a drug delivery company focused on oro-mucosal administration. The Company is developing low-risk oral sprays using its OroMist technology to reformulate existing pharmaceuticals.
Administering drugs through the oral mucosa (i.e.cheeks, tongue, gums and palate) has many potential benefits including ease of use, lower dosage, reduced side effects and faster response time.
Arovella's product pipeline includes ZolpiMist, an oral spray for the treatment of short-term insomnia. ZolpiMist has been approved by the TGA and is marketed in the USA. Arovella has the rights to ZolpiMist outside of the US and Canada.
Other products the Company has in development include oral sprays for the treatment of migraine headaches, motion sickness, drug resistant epilepsy and certain cancers.